Introduction
============

Blood glucose level is tightly regulated in healthy individuals.[@b1-jir-11-087],[@b2-jir-11-087] In situations of critical illness (eg, trauma, burn, or systemic inflammation), however, energy metabolism and glucose homeostasis are dysregulated.[@b1-jir-11-087]--[@b6-jir-11-087] The metabolic response to injury and sepsis is often called auto-cannibalism and includes a rapid mobilization of all substrate depots (eg, glycogen) and, accordingly, the loss of muscle mass and functional proteins, body fat, and the glucose storage.[@b3-jir-11-087]--[@b7-jir-11-087] During systemic inflammation, higher glucose requirement is covered by both increased hepatic glycogenolysis and gluconeogenesis leading to an initial hyperglycemic state.[@b5-jir-11-087],[@b6-jir-11-087],[@b8-jir-11-087] However, the glycogen depots are quickly exhausted after some time in case of higher glucose consumption. From this moment onward, glucose supply can only be achieved by an increased gluconeogenesis in the liver (temporary euglycemic phase in metabolic stress response).[@b5-jir-11-087],[@b6-jir-11-087],[@b8-jir-11-087] If this possibility of endogenous glucose production is also restricted or if the glucose uptake rate exceeds the rate of glucose production -- as it is the case for severe sepsis and inflammation -- finally hypoglycemia occurs.[@b5-jir-11-087],[@b6-jir-11-087],[@b8-jir-11-087] Clinical studies showed that hypoglycemia or hyperglycemia (defined as malglycemia) is associated with an increased risk of death.[@b9-jir-11-087]--[@b12-jir-11-087] In situation of critical illness, glucose as energy source for the brain is replaced almost completely by ketone bodies.[@b6-jir-11-087] Erythrocytes, however, are dependent on glucose as the sole source of energy (anaerobic glycolysis),[@b13-jir-11-087],[@b14-jir-11-087] even though under catabolic conditions, for a short time, the metabolism of 2,3-diphosphoglycerate to pyruvate and lactate is used for adenosine triphosphate (ATP) synthesis as well.[@b15-jir-11-087] "Starved" erythrocytes perish and hemoglobin and other cytoplasmic components, eg, lactate dehydrogenase and potassium, are released (so-called hemolysis).[@b14-jir-11-087] Cell-free hemoglobin and heme can contribute to organ dysfunction and death;[@b16-jir-11-087]--[@b19-jir-11-087] the pathologic mechanisms include nitric oxide (NO) consumption and local vasoconstriction, oxidative injury to lipid membranes, activation of the transcription factor NF-κB, endothelial injury, as well as iron-driven oxidative inhibition of glucose metabolism.[@b19-jir-11-087]--[@b22-jir-11-087] Thus, hemolysis can act as a kind of amplifier of the complex response to an infection or injury[@b23-jir-11-087],[@b24-jir-11-087] and worsen the outcome in patients with sepsis or trauma.[@b16-jir-11-087]--[@b19-jir-11-087] In contrast to other studies, glucose balance was not performed via insulin treatment,[@b9-jir-11-087],[@b25-jir-11-087],[@b26-jir-11-087] but via exogenous glucose supply.[@b27-jir-11-087]--[@b29-jir-11-087] Blood glucose level should be kept high, especially during hypoglycemia, and consequences such as hemolysis through glucose depletion in erythrocytes should be avoided.

In the present manuscript we wanted to investigate whether lipopolysaccharide (LPS)-induced hemolysis can be prevented or reduced if more glucose was present as a substrate for erythrocytes.

Materials and methods
=====================

Chemicals and Materials
-----------------------

LPS (from *Escherichia coli*, serotype 0111:B4) was purchased from Sigma-Aldrich (St. Louis, MO, USA), isoflurane from AbbVie Deutschland (Ludwigshafen, Germany), ketamine 10% from Ceva (Düsseldorf, Germany), lidocaine (Xylocaine 1%) from AstraZeneca (Wedel, Germany), medical oxygen from Air Liquide (Düsseldorf, Germany), Ringer's solution from Fresenius Kabi (Bad Homburg, Germany), and 2.0 mL self-filling arterial samplers containing 80 IU electrolyte-balanced heparin (PICO50) from Radiometer Medical (Brønshøj, Denmark). Portex catheters (0.58 mm i.d./0.96 mm o.d.) were obtained from Smith Medical International (Grasbrunn, Germany).

Animals
-------

Male Wistar rats (390--520 g, from Envigo, formerly Harlan Laboratories, Horst, Netherlands) received human care according to standards of the Federation of European Laboratory Animal Science Association. The experimental procedure was reviewed and approved by the local Animal Care and Use Committee with the permit number Az. 84-02.04.2013.A015 (Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen, Recklinghausen, Germany). Rats were kept under standardized conditions of temperature (22 ± 1°C), humidity (55 ± 5%), and 12-h/12-h light/dark cycles (06:00 a.m. light on/06:00 p.m. light off, standard time) with free access to food (ssniff-Spezialdiäten, Soest, Germany) and water.

Anesthesia, analgesia and surgical procedure
--------------------------------------------

Rats were anesthetized with isoflurane and received ketamine and lidocaine for analgesia as already described.[@b30-jir-11-087] Afterwards, catheters were inserted in femoral artery and vein and perfused with Ringer's solution to maintain the functionality of the catheters. At the end of the experiment, animals were sacrificed by cardiac incision under deep isoflurane anesthesia.

Experimental groups
-------------------

Experiments were performed with overall 40 rats. Sham control group rats received Ringer's solution at a rate of 7 mL/kg and h over a total period of 300 min. Systemic inflammation was accomplished by continuous LPS infusion over a total period of 300 min. Glucose was supplied either moderately or excessively during systemic inflammation simultaneously with the LPS infusion. During moderate glucose supply, rats received LPS in a 1% solution of glucose/kg and h. During excessive glucose supply, rats received LPS in a 3% solution of glucose/kg and h. The following experimental groups were compared: SHAM (sham control group): Ringer's solution, 300 min, n = 12 ratsLPS (lipopolysaccharide group): 1 mg LPS in Ringer's solution/kg and h, 300 min, n = 12 ratsLPS+MG (LPS moderate glucose group): 1 mg LPS/kg and h + 70 mg glucose/kg and h, 300 min, n = 8 ratsLPS+EG (LPS excessive glucose group): 1 mg LPS/kg and h + 210 mg glucose/kg and h, 300 min, n = 8 rats

Assessment of vital, blood, and plasma parameters
-------------------------------------------------

Systemic blood pressure, heart rates, and breathing rates were determined in 10 min intervals as already described.[@b30-jir-11-087] Core temperature was kept constant above 37°C with an underlying heated operating table and by covering the rats with aluminum foil.

Blood samples were taken from the femoral artery catheter immediately before starting the LPS infusion (T = 0 min) and at any further hour (T = 60, 120, 180, 240, 300 min) using self-filling arterial samplers (containing 80 IU electrolyte-balanced heparin). Blood gases, acid-base parameters, hematocrit, electrolytes, as well as glucose and lactate concentrations were assessed with a blood gas analyzer equipped with additional electrodes (ABL 715; Radiometer, Københaven, Denmark). Heparinized blood plasma was obtained from the blood samples by centrifugation. Concentration of cell-free hemoglobin was measured using the spectroscopic Soret band method. Activities of lactate dehydrogenase, aminotransferases, and creatine kinase as well as creatinine concentration were determined with a fully automated clinical chemistry analyzer (Vitalab Selectra E; VWR International, Darmstadt, Germany). For each blood sampling, rats were substituted with 0.3 mL of Ringer's solution.[@b30-jir-11-087] At the end of the experiments (T = 300 min), final blood samples were taken in one-tenth volume of citrate (3.13%). Citrate blood plasma was used for thromboelastometry (ROTEM; TEM International, München, Germany). The kinetics of clot formation was analyzed by thromboelastometry using INTEM or EXTEM test and described in numerical parameters.[@b30-jir-11-087]

Data analysis and statistics
----------------------------

Experiments were performed with 12 rats per group for SHAM and LPS and 8 rats per group for LPS+MG and LPS+EG. The included number of rats was set on empirical basis. Randomization was done by lottery before the start of the study. The data are expressed as mean values ± standard error of mean, and analyses were carried out using GraphPad Prism 6 (GraphPad Prism Software Onc, San Diego, CA, USA). All data were tested for normality using the D'Agostino-Pearson omnibus normality test. For all independent variables (vital, blood, and plasma parameters), which were determined to have a Gaussian distribution, comparison among multiple groups was performed using one-way analysis of variance followed by Dunnet's post hoc multiple comparisons test. For those that did not pass the normality test, Kruskal-Wallis test was used for the significance analysis followed by Dunn's correction for multiple comparisons. Differences in parameters over time within each group were determined by repeated-measures one-way analysis of variance (ANOVA). An a priori alpha error *P* of less than 0.05 was considered statistically significant (95% confidence interval). Outliers were defined using box-and-whiskers plots.

Results
=======

All rats, both treated and untreated with LPS, survived the whole experimental time of 300 min. Continuous infusion of LPS led to hyperthermia, tachycardia, and tachypnea ([Table 1](#t1-jir-11-087){ref-type="table"}). It affected the systemic blood pressure (acute blood pressure elevation within the first hour and continually high blood pressure after approximately 140 minutes until the end of the experiments; [Figure 1](#f1-jir-11-087){ref-type="fig"}), the electrolyte homeostasis (hypocalcemia, hyperkalemia, and hypernatremia; [Table 1](#t1-jir-11-087){ref-type="table"}), and the energy metabolism (lactate formation and metabolic acidosis with compensatory hyperventilation, early hyperglycemia, and finally hypoglycemia; [Table 1](#t1-jir-11-087){ref-type="table"}; [Figure 2](#f2-jir-11-087){ref-type="fig"}). Rats treated with LPS also showed severe organ and tissue injury (significant increases in plasma concentrations of transaminases, lactate dehydrogenase, and creatine kinase; [Table 1](#t1-jir-11-087){ref-type="table"}). Furthermore, a significant increase of cell-free hemoglobin could be measured indicating massive hemolysis ([Table 1](#t1-jir-11-087){ref-type="table"}; [Figure 1](#f1-jir-11-087){ref-type="fig"}). LPS infusion led to a significant increase of clotting time as well as a significant decrease of maximum clot firmness in comparison to SHAM ([Table 2](#t2-jir-11-087){ref-type="table"}).

Both moderate and excessive glucose supply during systemic inflammation reduced LPS-induced increase in systemic blood pressure ([Figure 1](#f1-jir-11-087){ref-type="fig"}). The acute blood pressure elevation within the first hour of LPS infusion as well as the later LPS-related continually high blood pressure was reduced significantly by intravenous infusion of moderate or excessive amounts of glucose. At the end of the experiments, however, a slight drop in systemic blood pressure was noticed for additional glucose supply ([Table 1](#t1-jir-11-087){ref-type="table"}; [Figure 1](#f1-jir-11-087){ref-type="fig"}).

Glucose supply also diminished LPS-induced release of hemoglobin from erythrocytes. Hemolysis was reduced significantly 120 minutes after starting of LPS infusion till the end of experiment ([Table 1](#t1-jir-11-087){ref-type="table"}; [Figure 1](#f1-jir-11-087){ref-type="fig"}).

Excessive but not moderate glucose supply increased significantly blood glucose level during systemic inflammation, during early hyperglycemia but even more clearly during final hypoglycemia ([Table 1](#t1-jir-11-087){ref-type="table"}; [Figure 2](#f2-jir-11-087){ref-type="fig"}). Moderate glucose supply, however, did not change LPS-induced alterations in blood glucose level.

Additional glucose supply did not beneficially affect LPS-related functional impairment and tissue injury as indicated by increased lactate formation, electrolyte disturbances, and raised liver and renal function tests (transaminases as well as creatinine and lactate dehydrogenase). On the contrary, plasma concentrations of lactate, lactate dehydrogenase, aspartate aminotransferase, and creatinine were even aggravated, though not always significantly, following excessive glucose supply ([Table 1](#t1-jir-11-087){ref-type="table"}; [Figures 1](#f1-jir-11-087){ref-type="fig"} and [2](#f2-jir-11-087){ref-type="fig"}).

Additional glucose supply did not reduce LPS-induced alterations in the parameters of thromboelastometry ([Table 2](#t2-jir-11-087){ref-type="table"}).

Discussion
==========

In the present study, we demonstrated for the first time that the cross-talk between glucose and heme metabolism in LPS-mediated systemic inflammation could also be bidirectional.

The consequences of sepsis and inflammation are complex and far reaching.[@b31-jir-11-087],[@b32-jir-11-087] Metabolism is converted to catabolism in order to provide all substrates necessary for the immune response and healing process in sufficient quantities.[@b3-jir-11-087]--[@b7-jir-11-087] Metabolic disorders, such as hyperglycemia or hypoglycemia, are associated with an increased risk of death.[@b9-jir-11-087]--[@b12-jir-11-087] The experimental model of continuous LPS infusion used in the present study reflects most pathophysiological changes known from clinical severe sepsis.[@b30-jir-11-087],[@b33-jir-11-087],[@b34-jir-11-087] So, continuous infusion of LPS in our model led to an early hyperglycemic pre-shock state followed by a later hypoglycemic shock state. It induced severe functional impairment and tissue injury.

In addition to metabolic and hemodynamic changes, release of cell-free hemoglobin from erythrocytes (hemolysis) often occurs during systemic inflammation and sepsis.[@b16-jir-11-087]--[@b19-jir-11-087] In the present study, we also found massive hemolysis following infusion with LPS. There are many possible mechanisms leading to hemolysis -- we recently demonstrated two: in an in vitro study, we could show that LPS as an amphiphilic molecule weakens the membrane of erythrocytes, leading to hemolysis.[@b35-jir-11-087],[@b36-jir-11-087] In another in vivo study, we demonstrated that diminishing of the LPS-induced disseminated intravascular coagulation is also capable of diminishing hemolysis (Brauckmann, 2017, unpublished). If the metabolism is changed to catabolism, many glucose-dependent organs can resort to other energy sources. For example, the brain uses ketone bodies as energy source when the supply of glucose is restricted[@b6-jir-11-087]. On the other hand, erythrocytes cannot easily change their energy sources, since erythrocytes are imperatively dependent on anaerobic glycolysis.[@b13-jir-11-087],[@b14-jir-11-087] During hypoglycemia, as it could be the case for severe sepsis and inflammation, the erythrocytes are cut off from their energy source. "The energy-less erythrocyte is lost"; it will cease to exist and subsequent hemolysis occurs.[@b14-jir-11-087]

Wolfe and coworkers already described that infusion of glucose at a rate of 4 mg glucose/kg and min over a total time of 120 min (corresponds to 240 mg/kg and h or cumulatively 480 mg/kg) suppressed endogenous gluconeogenesis in healthy volunteers.[@b27-jir-11-087] In septic patients, glucose infusion at a rate of 4 mg glucose/kg and min decreased hepatic glycogenolysis but not gluconeogenesis.[@b27-jir-11-087] Endogenous glucose production in healthy man was suppressed at a rate of 120 mg glucose/kg and h in 120 min (corresponds to 2 mg glucose/kg and min).[@b28-jir-11-087] The absolute degree of suppression was reached at a rate of 240 mg glucose/kg and h in 120 min;[@b28-jir-11-087] at higher doses no further suppression was measurable.[@b27-jir-11-087] Glucose overload, on the contrary, enhanced hyperglycemia[@b7-jir-11-087],[@b37-jir-11-087] and increased norepinephrine release.[@b38-jir-11-087] According to the studies of Wolfe et al and due to the fact that glucose overload is detrimental, we used in our study a low dosage (moderate glucose supply: 70 mg glucose/kg and h over a time of 300 min, cumulative: 350 mg glucose/kg) -- an effect on the glucose level is not expected -- and a high dosage (excessive glucose supply: 210 mg glucose/kg and h over a time of 300 min, cumulative: 1050 mg glucose/kg) -- an effect on the glucose level is expected. Indeed, the excessive but not moderate glucose supply had an effect on the plasma concentration of glucose.

Surprisingly, both moderate and excessive glucose supply reduced LPS-induced hemolysis. An indirect effect of glucose as modulator in the inflammation-related activation of coagulation[@b31-jir-11-087],[@b39-jir-11-087] can be excluded, since neither moderate nor excessive glucose supply affected LPS-induced alterations in clot formation kinetics. Ultimately, the additional administration of low glucose seems to protect the erythrocytes from "starvation". It has long been known that a sufficient amount of glucose has a beneficial effect on the quality of stored blood by maintaining acceptable levels of ATP and 2,3-diphosphoglycerate.[@b40-jir-11-087]--[@b42-jir-11-087] Exposure of erythrocytes to high glucose concentrations can reduce hemolysis in vitro.[@b43-jir-11-087],[@b44-jir-11-087] Thus, there are many indications that moderate glucose infusion might reduce hemolysis during sepsis or inflammation. A consequential effect of diminished hemolysis, as visible in our study, might be the stabilization of the blood pressure through intravenous glucose supply over a certain period of time. Among others, one explanation could be a lack of the NO-scavenging effect through cell-free heme and hemoglobin.[@b20-jir-11-087] However, this is rather a result of a reduced hemolysis than an increased glucose concentration. In other words, if less cell-free hemoglobin is released, in turn, less NO would also be trapped, and blood pressure would not increase in consequence of hemolysis.[@b19-jir-11-087],[@b20-jir-11-087] However, at this point, it cannot be excluded that glucose has a direct effect on NO level or even blood pressure.

An excessive accumulation of cell-free heme following hemolysis, moreover, can influence the glucose metabolism by iron-driven oxidative inhibition of the liver glucose-6-phosphatase -- an enzyme important for endogenous glucose production via gluconeogenesis and glycogenolysis.[@b22-jir-11-087] Thus, an unidirectional relationship that the accumulation of cell-free hemoglobin or heme affects glucose metabolism during sepsis has already been described by Weis et al.[@b22-jir-11-087] We demonstrated that the crosstalk between glucose and heme metabolism could also be bidirectional.

In addition to the reduction of the LPS-induced hemolysis excessive glucose supply, however, might not just increase blood glucose level up to hyperglycemia but also enhance functional impairment and liver injury (increases in plasma alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase activity). Liver damage due to large amounts of glucose, as seen in the present study, has already been described by other working groups.[@b45-jir-11-087] An injured liver is incapable of metabolizing lactate neither back to glucose (gluconeogenesis) nor to carbon dioxide and water.[@b46-jir-11-087],[@b47-jir-11-087] The further increase in plasma lactate, as has been found for excessive glucose supply during systemic inflammation ([Figure 2](#f2-jir-11-087){ref-type="fig"}), therefore just reports about an impaired liver function.

The absolute degree of hemolysis reduction was reached by moderate glucose supply; a further reduction following excessive glucose supply was not measurable. It seems that the mechanisms leading to hemolysis during sepsis and systemic inflammation are synergistic or additive. A proportion through the coagulation effect still exists, as is the proportion of the direct membrane effects. Nevertheless, a reduction of hemolysis by 35% only by the addition of a small amount of glucose is another step to minimize mortality during systemic inflammation.
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![Effect of moderate (MG) and excessive glucose supply (EG) on systemic blood pressure (**A**) and plasma concentration of cell-free hemoglobin (**B**) during systemic inflammation. Lipopolysaccharide (LPS) was infused at a rate of 1 mg/kg and h over a period of 300 min to induce systemic inflammation in male Wistar rats. Glucose was supplied either moderately (LPS+MG: 1 mg LPS/kg and h + 70 mg glucose/kg and h) or excessively (LPS+EG: 1 mg LPS/kg and h + 210 mg glucose/kg and h) during systemic inflammation. Systemic blood pressure and plasma concentration of cell-free hemoglobin are shown as mean values ± standard errors of mean.](jir-11-087Fig1){#f1-jir-11-087}

![Effect of moderate (MG) and excessive glucose supply (EG) on plasma concentrations of glucose (**A**) and lactate (**B**) during systemic inflammation. Lipopolysaccharide (LPS) was infused at a rate of 1 mg/kg and h over a period of 300 min to induce systemic inflammation in male Wistar rats. Glucose was supplied either moderately (LPS+MG: 1 mg LPS/kg and h + 70 mg glucose/kg and h) or excessively (LPS+EG: 1 mg LPS/kg and h + 210 mg glucose/kg and h) during systemic inflammation. Plasma concentrations of glucose and lactate are shown as mean values ± standard errors of mean.](jir-11-087Fig2){#f2-jir-11-087}

###### 

Effect of moderate (MG) and excessive glucose (EG) supply on vital, blood, and plasma parameters[a](#tfn1-jir-11-087){ref-type="table-fn"} during systemic inflammation

  Parameters                             SHAM 300 min   (0 min)         Lipopolysaccharide (LPS) 300 min          LPS+MG 300 min                                  LPS+EG 300 min
  -------------------------------------- -------------- --------------- ----------------------------------------- ----------------------------------------------- ---------------------------------------
  **Systemic blood pressure (mmHg)**     97 ± 4         (89 ± 3)        104 ± 6^n.s.\ vs.\ SHAM^                  91 ± 6^n.s.\ vs.\ LPS^                          79 ± 7*^P\ =^* ^0.0109\ vs.\ LPS^
  **Heart rate (min**^−^**^1^)**         334 ± 8        (297 ± 6)       392 ± 12*^P^* ^=\ 0.0015\ vs.\ SHAM^      375 ± 6^n.s.\ vs.\ LPS^                         381 ± 7^n.s.\ vs.\ LPS^
  **Breathing rate (min**^−^**^1^)**     47 ± 3         (56 ± 2)        60 ± 3*^P^* ^=\ 0.0148\ vs.\ SHAM^        59 ± 3 ^n.s.\ vs.\ LPS^                         50 ± 5^n.s.\ vs.\ LPS^
  **Body temperature (°C)**              37.7 ± 0.1     (37.5 ± 0.1)    38.1 ± 0.2^n.s.\ vs.\ SHAM^               38.1 ± 0.1^n.s.\ vs.\ LPS^                      38.1 ± 0.1^n.s.\ vs.\ LPS^
  **pH**                                 7.26 ± 0.03    (7.30 ± 0.01)   7.27 ± 0.02^n.s.\ vs.\ SHAM^              7.32 ± 0.031^n.s.\ vs.\ LPS^                    7.33 ± 0.031^n.s.\ vs.\ LPS^
  **pCO~2~ (mmHg)**                      49 ± 2         (45 ± 1)        37 ± 2*^P^* ^=\ 0.0012\ vs.\ SHAM^        34 ± 3^n.s.\ vs.\ LPS^                          33 ± 2 ^n.s.\ vs.\ LPS^
  **Base excess (mmol/L)**               −5.1 ± 1.4     (−3.5 ± 0.5)    −9.5 ± 0.7*^P^* ^=\ 0.0060\ vs.\ SHAM^    -8.5 ± 0.5^n.s.\ vs.\ LPS^                      −8.3 ± 0.8^n.s.\ vs.\ LPS^
  **HCO~3~**^−^ **(mmol/L)**             19.9 ± 1.1     (21.4 ± 0.4)    16.8 ± 0.5*^P^* ^=\ 0.0144\ vs.\ SHAM^    17.6 ± 0.4^n.s.\ vs.\ LPS^                      17.6 ± 0.6^n.s.\ vs.\ LPS^
  **pO~2~ (mmHg)**                       342 ± 26       (353 ± 21)      334 ± 32^n.s.\ vs.\ SHAM^                 358 ± 18^n.s.\ vs.\ LPS^                        345 ± 15^n.s.\ vs.\ LPS^
  **K^+^ (mmol/L)**                      4.8 ± 0.1      (5.0 ± 0.1)     5.1 ± 0.1^n.s.\ vs.\ SHAM^                5.2 ± 0.1^n.s.\ vs.\ LPS^                       5.3 ± 0.2^n.s.\ vs.\ LPS^
  **Na^+^ (mmol/L)**                     140 ± 0        (141 ± 0)       142 ± 1*^P^* ^=\ 0.0244\ vs.\ SHAM^       140 ± 1^n.s.\ vs.\ LPS^                         139 ± 1*^P^* ^=\ 0.0002\ vs.\ LPS^
  **Cl**− **(mmol/L)**                   114 ± 1        (115 ± 1)       119 ± 1*^P^* ^=\ 0.0005\ vs.\ SHAM^       118 ± 1^n.s.\ vs.\ LPS^                         116 ± 1^n.s.\ vs.\ LPS^
  **Ca^2+^ (mmol/L)**                    1.47 ± 0.03    (1.53 ± 0.03)   1.30 ± 0.05*^P^* ^=\ 0.0036\ vs.\ SHAM^   1.30 ± 0.03^n.s.\ vs.\ LPS^                     1.29 ± 0.04^n.s.\ vs.\ LPS^
  **Alanine aminotransferase (U/L)**     77 ± 16        (59 ± 10)       336 ± 64*^P^* ^\<\ 0.0001\ vs.\ SHAM^     181 ± 30^n.s.\ vs.\ LPS^                        356 ±126^n.s.\ vs.\ LPS^
  **Aspartate aminotransferase (U/L)**   98 ± 11        (68 ± 5)        427 ± 61*^P^* ^=\ 0.0004\ vs.\ SHAM^      433 ± 37^n.s.\ vs.\ LPS^                        838 ± 357^n.s.\ vs.\ LPS^
  **Lactate dehydrogenase (U/L)**        199 ± 37       (159 ± 26)      1345 ± 146*^P^* ^\<\ 0.0001\ vs.\ SHAM^   1326 ± 150^n.s.\ vs.\ LPS^                      2037 ± 393*^P^* ^=\ 0.0336\ vs.\ LPS^
  **Creatine kinase (U/L)**              148 ± 33       (364 ± 55)      550 ± 83*^P^* ^=\ 0.0006\ vs.\ SHAM^      586 ± 103^n.s.\ vs.\ LPS^                       544 ± 83^n.s.\ vs.\ LPS^
  **Creatinine (mg/dL)**                 0.71 ± 0.10    (0.71 ± 0.07)   1.06 ± 0.10^n.s.\ vs.\ SHAM^              1.41 ± 0.21^n.s.\ vs.\ LPS^                     1.52 ± 0.18 ^n.s.\ vs.\ LPS^
  **Glucose (mg/dL)**                    151 ± 8        (147 ± 4)       46 ± 6*^P^* ^\<\ 0.0001\ vs.\ SHAM^       53 ± 3^n.s.\ vs.\ LPS^                          97 ± 17*^P^* ^=\ 0.0014\ vs.\ LPS^
  **Lactate (mmol/L)**                   1.0 ± 0.1      (0.9 ± 0.1)     2.7 ± 0.4*^P^* ^\<\ 0.0001\ vs.\ SHAM^    3.0 ± 0.2^n.s.\ vs.\ LPS^                       3.2 ± 0.2^n.s.\ vs.\ LPS^
  **Hematocrit (%)**                     37.6 ± 0.9     (40.7 ± 0.8)    36.1 ± 1.3^n.s.\ vs.\ SHAM^               35.5 ± 0.9^n.s.\ vs.\ LPS^                      35.2 ± 0.9^n.s.\ vs.\ LPS^
  **Cell-free hemoglobin (µmol/L)**      14.4 ± 3.1     (11.1 ± 0.8)    43.2 ± 5.8*^P^* ^\<\ 0.0001\ vs.\ SHAM^   28.1 ± 2.7*^P^* ^=\ 0.0525\ vs.\ LPS\ (n.s.)^   27.2 ± 3.9*^P^* ^=\ 0.0384\ vs.\ LPS^

**Notes:**

Vital parameters, blood gases, electrolytes, plasma enzyme activities, as well as the plasma concentration of creatinine, glucose, lactate, and cell-free hemoglobin of the groups SHAM (n = 12), LPS (n = 12), LPS+MG (n = 8), and LPS+EG (n = 8) are shown (mean values ± standard error of mean) either before the beginning of the LPS infusion (baseline, T = 0 min) or at T = 300 min. Baseline values of the SHAM group were not significantly different from those of the other groups. Lipopolysaccharide (LPS) was infused at a rate of 1 mg/kg and h over a period of 300 min to induce systemic inflammation in male Wistar rats. Glucose was supplied either moderately (LPS+MG: 1 mg LPS/kg and h + 70 mg glucose/kg and h) or excessively (LPS+EG: 1 mg LPS/kg and h + 210 mg glucose/kg and h) during systemic inflammation. n.s. = not significant.

###### 

Effect of moderate (MG) and excessive glucose (EG) supply on parameters of thromboelastometry[a](#tfn2-jir-11-087){ref-type="table-fn"} during systemic inflammation

  Parameters     SHAM 300 min   LPS 300 min                               LPS+MG 300 min               LPS+EG 300 min
  -------------- -------------- ----------------------------------------- ---------------------------- ----------------------------
  EXTEM                                                                                                
  **CT (s)**     38 ± 4         2691 ± 435*^P^* ^\<\ 0.0001\ vs.\ SHAM^   2435 ± 414^n.s.\ vs.\ LPS^   1988 ± 444^n.s.\ vs.\ LPS^
  **MCF (mm)**   25.0 ± 1.1     2.5 ± 0.8*^P^* ^\<\ 0.0001\ vs.\ SHAM^    1.4 ± 0.8^n.s.\ vs.\ LPS^    2.8 ± 1.4^n.s.\ vs.\ LPS^
  INTEM                                                                                                
  **CT (s)**     126 ± 4        2906 ± 375*^P^* ^\<\ 0.0001\ vs.\ SHAM^   1980 ± 619^n.s.\ vs.\ LPS^   1670 ± 713^n.s.\ vs.\ LPS^
  **MCF (mm)**   19.4 ± 1.1     0.7 ± 0.4*^P^* ^\<\ 0.0001\ vs.\ SHAM^    2.8 ± 1.3^n.s.\ vs.\ LPS^    3.0 ± 0.9^n.s.\ vs.\ LPS^

**Notes:**

The clotting time (CT) and the maximum clot firmness (MCF) of the groups SHAM (n = 12), LPS (n = 12), LPS+MG (n = 8), and LPS+EG (n = 8) are shown (mean values ± standard error of mean) for time point T = 300 min. Lipopolysaccharide (LPS) was infused at a rate of 1 mg/kg and h over a period of 300 min to induce systemic inflammation in male Wistar rats. Glucose was supplied either moderately (LPS+MG: 1 mg LPS/kg and h + 70 mg glucose/kg and h) or excessively (LPS+EG: 1 mg LPS/kg and h + 210 mg glucose/kg and h) during systemic inflammation. n.s. = not significant.
